Dr. Rini on Cytoreductive Nephrectomy in RCC

Video

In Partnership With:

Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses the role of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma (RCC).

Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses the role of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma (RCC).

For the last 20 years, subsequent cytoreductive nephrectomy and interferon has been the standard treatment for patients with metastatic RCC, Rini says. However, physicians are starting to rethink this decision because of the advent of targeted therapies.

Rini says several retrospective analyses have supported that cytoreductive nephrectomy should remain the standard treatment. However, patient selection bias prevents too much weight being placed on these retrospective studies, Rini says.

Two prospective studies are underway, but it will be some time before those read out.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,